Altogether, our results indicate that higher tumor gene expression and/or circulating levels of IL-1 ligands may be associated with favorable survival outcomes in cetuximab-based therapy-treated HNSCC patients. The gene discussed is IL1A; the disease is head and neck squamous cell carcinoma.